Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 11/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.43 |
| ▸ | AURKA | O14965 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6759307 | 0.84 | BDKRB1 (0.42) | BDKRB1KDRMAPT | |
| SCHEMBL20722727 | 0.80 | KDM4E (0.62) | KDM4EALDH1A1HPGDHSD17B10KDR | |
| SCHEMBL7012858 | 0.77 | RPS6KB1 (0.64) | KDM4EALDH1A1HPGDHSD17B10KDR | |
| SCHEMBL30595572 | 0.77 | KDR (0.62) | KDM4EALDH1A1HPGDHSD17B10KDR | |
| SCHEMBL5261234 | 0.77 | KDR (0.62) | KDM4EALDH1A1HPGDHSD17B10KDR | |
| SCHEMBL29957028 | 0.72 | EGFR (0.50) | HPGDHSD17B10KDRSMN1; SMN2HTT | |
| SCHEMBL3714863 | 0.72 | ALDH1A1 (0.58) | KDM4EALDH1A1HPGDHSD17B10RPS6KB1 | |
| SCHEMBL31204910 | 0.72 | ALDH1A1 (0.58) | KDM4EALDH1A1HPGDHSD17B10RPS6KB1 | |
| SCHEMBL5554912 | 0.72 | RPS6KB1 (0.65) | KDM4EALDH1A1HPGDHSD17B10RPS6KB1 | |
| SCHEMBL31204891 | 0.72 | RPS6KB1 (0.65) | KDM4EALDH1A1HPGDHSD17B10RPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040034064-A1 | 2-(biarylalkyl)amino-3-(alkanoylamino)pyridine derivatives | KUDUK SCOTT D (US) | 2004-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034064-A1 | 2-(biarylalkyl)amino-3-(alkanoylamino)pyridine derivatives | BDKRB1, BDKRB2, LTB4R2 | BDKRB1 1/4885KDM4E 4352/4885ALDH1A1 2087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.